原发性胆汁性胆管炎为何对免疫抑制药物无反应？
Why Doesn't Primary Biliary Cholangitis Respond to Immunosuppressive Medications?
作者信息
Molinaro Antonio, Marschall Hanns-Ulrich
机构信息
Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, Sahlgrenska Academy, SE-413 45 Gothenburg, Sweden.
出版信息
Curr Hepatol Rep. 2017;16(2):119-123. doi: 10.1007/s11901-017-0345-y. Epub 2017 Apr 27.
Abstract
PURPOSE OF REVIEW
The purpose of this review is to discuss reasons why immunosuppressive therapy so far failed in Primary Biliry Cholangitis.
RECENT FINDINGS
Even targeted immunosuppressive therapy seems ineffective or potentially harmful.
SUMMARY
Bile acid-mediated cholangiocyte damage, facilitated by insufficient bicarbonate secretion, seems to attenuate the anti-inflammatory and anti-fibrotic actions of immunosuppressant and immunomodulatory drugs in a clinically significant way.
摘要
综述目的
本综述旨在探讨免疫抑制治疗迄今在原发性胆汁性胆管炎中失败的原因。
最新发现
即使是靶向免疫抑制治疗似乎也无效或有潜在危害。
总结
胆汁酸介导的胆管细胞损伤，因碳酸氢盐分泌不足而加剧，似乎以一种具有临床意义的方式削弱了免疫抑制剂和免疫调节药物的抗炎和抗纤维化作用。
相似文献
1
Why Doesn't Primary Biliary Cholangitis Respond to Immunosuppressive Medications?原发性胆汁性胆管炎为何对免疫抑制药物无反应？
Curr Hepatol Rep. 2017;16(2):119-123. doi: 10.1007/s11901-017-0345-y. Epub 2017 Apr 27.
2
Obeticholic acid for the treatment of primary biliary cholangitis.奥贝胆酸用于治疗原发性胆汁性胆管炎。
Expert Opin Pharmacother. 2016 Sep;17(13):1809-15. doi: 10.1080/14656566.2016.1218471. Epub 2016 Aug 9.
3
Chronic cholestatic diseases.慢性胆汁淤积性疾病
J Hepatol. 2000;32(1 Suppl):129-40. doi: 10.1016/s0168-8278(00)80421-3.
5
Obeticholic acid for the treatment of primary biliary cholangitis in adult patients: clinical utility and patient selection.奥贝胆酸用于治疗成年原发性胆汁性胆管炎患者：临床应用及患者选择
Hepat Med. 2016 Sep 1;8:89-95. doi: 10.2147/HMER.S91709. eCollection 2016.
6
Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis.奥贝胆酸治疗原发性胆汁性胆管炎的长期临床影响和成本效益。
Hepatology. 2017 Mar;65(3):920-928. doi: 10.1002/hep.28932. Epub 2017 Jan 17.
7
Novel and emerging therapies for cholestatic liver diseases.胆汁淤积性肝病的新型和新兴疗法。
Liver Int. 2018 Sep;38(9):1520-1535. doi: 10.1111/liv.13880. Epub 2018 Jun 14.
8
Role of the bicarbonate-responsive soluble adenylyl cyclase in cholangiocyte apoptosis in primary biliary cholangitis; a new hypothesis.碳酸氢盐反应性可溶性腺苷酸环化酶在原发性胆汁性胆管炎胆管细胞凋亡中的作用；一个新假说。
Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt B):1232-1239. doi: 10.1016/j.bbadis.2017.09.022. Epub 2017 Sep 28.
9
Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis.原发性胆汁性肝硬化和原发性硬化性胆管炎的医学治疗。
Clin Rev Allergy Immunol. 2005 Apr;28(2):135-45. doi: 10.1385/CRIAI:28:2:135.
10
Obeticholic acid in primary biliary cholangitis: where we stand.原发性胆汁性胆管炎中的奥贝胆酸：我们的立场。
Curr Opin Gastroenterol. 2019 May;35(3):191-196. doi: 10.1097/MOG.0000000000000525.
引用本文的文献
1
Emerging Therapeutic Strategies in The Fight Against Primary Biliary Cholangitis.原发性胆汁性胆管炎治疗新策略
J Clin Transl Hepatol. 2023 Aug 28;11(4):949-957. doi: 10.14218/JCTH.2022.00398. Epub 2023 Mar 16.
2
Belimumab treatment in autoimmune hepatitis and primary biliary cholangitis - a case series.贝利尤单抗治疗自身免疫性肝炎和原发性胆汁性胆管炎——病例系列
J Transl Autoimmun. 2023 Jan 14;6:100189. doi: 10.1016/j.jtauto.2023.100189. eCollection 2023.
3
Characteristics and Inpatient Outcomes of Primary Biliary Cholangitis and Autoimmune Hepatitis Overlap Syndrome.原发性胆汁性胆管炎与自身免疫性肝炎重叠综合征的特征及住院结局
J Clin Transl Hepatol. 2021 Jun 28;9(3):392-398. doi: 10.14218/JCTH.2021.00008. Epub 2021 Mar 11.
4
Animal Models of Autoimmune Liver Diseases: a Comprehensive Review.自身免疫性肝病的动物模型：全面综述。
Clin Rev Allergy Immunol. 2020 Apr;58(2):252-271. doi: 10.1007/s12016-020-08778-6.
5
Promoter hypermethylation of the gene in PBC.原发性胆汁性胆管炎中该基因的启动子高甲基化
JHEP Rep. 2019 Jun 7;1(3):145-153. doi: 10.1016/j.jhepr.2019.05.006. eCollection 2019 Sep.
本文引用的文献
1
Primary biliary cholangitis in 2016: High-definition PBC: biology, models and therapeutic advances.2016年原发性胆汁性胆管炎：高清原发性胆汁性胆管炎：生物学、模型及治疗进展
Nat Rev Gastroenterol Hepatol. 2017 Feb;14(2):76-78. doi: 10.1038/nrgastro.2016.201. Epub 2017 Jan 11.
2
Systematic review: recurrent autoimmune liver diseases after liver transplantation.系统评价：肝移植后复发性自身免疫性肝病
Aliment Pharmacol Ther. 2017 Feb;45(4):485-500. doi: 10.1111/apt.13894. Epub 2016 Dec 12.
3
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.奥贝胆酸治疗原发性胆汁性胆管炎的安慰剂对照临床试验。
N Engl J Med. 2016 Aug 18;375(7):631-43. doi: 10.1056/NEJMoa1509840.
4
Novel therapeutics for primary biliary cholangitis: Toward a disease-stage-based approach.原发性胆汁性胆管炎的新型治疗方法：基于疾病阶段的治疗方法。
Autoimmun Rev. 2016 Sep;15(9):870-6. doi: 10.1016/j.autrev.2016.07.003. Epub 2016 Jul 6.
5
Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism.胆汁酸与肠道微生物群的相互作用及其对宿主代谢的影响。
Cell Metab. 2016 Jul 12;24(1):41-50. doi: 10.1016/j.cmet.2016.05.005. Epub 2016 Jun 16.
6
Alterations and correlations of the gut microbiome, metabolism and immunity in patients with primary biliary cirrhosis.原发性胆汁性肝硬化患者的肠道微生物组、代谢和免疫的改变和相关性。
Environ Microbiol. 2016 Jul;18(7):2272-86. doi: 10.1111/1462-2920.13401.
7
Chronic expression of interferon-gamma leads to murine autoimmune cholangitis with a female predominance.γ-干扰素的慢性表达导致以雌性为主的小鼠自身免疫性胆管炎。
Hepatology. 2016 Oct;64(4):1189-201. doi: 10.1002/hep.28641. Epub 2016 Jun 15.
8
Soluble Adenylyl Cyclase Regulates Bile Salt-Induced Apoptosis in Human Cholangiocytes.可溶性腺苷酸环化酶调节胆盐诱导的人胆管细胞凋亡。
Hepatology. 2016 Aug;64(2):522-34. doi: 10.1002/hep.28550. Epub 2016 Apr 15.
9
Genetic Risk and the Development of Autoimmune Liver Disease.遗传风险与自身免疫性肝病的发展
Dig Dis. 2015;33 Suppl 2:13-24. doi: 10.1159/000440706. Epub 2015 Dec 7.
10
Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: A proof-of-concept study.乌司奴单抗治疗熊去氧胆酸应答不足的原发性胆汁性胆管炎患者：概念验证研究。
Hepatology. 2016 Jul;64(1):189-99. doi: 10.1002/hep.28359. Epub 2016 Jan 14.
Zotero 插件